Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy

被引：0
|
作者：
Riddle, M
Rosenstock, J
机构：
[1] Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
150
引用
收藏
页码：A52 / A52
页数：1
相关论文
共 50 条
  • [21] Effect of insulin degludec on glycaemic control and nocturnal hypoglycaemia compared with insulin glargine: a 1-year trial in insulin-naive patients with type 2 diabetes
    Zinman, B.
    Philis-Tsimikas, A.
    Handelsman, Y.
    Rodbard, H. W.
    Cariou, B.
    Johansen, T.
    Endahl, L.
    Mathieu, C.
    DIABETOLOGIA, 2012, 55 : S22 - S22
  • [22] Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes
    Pieber, TR
    Treichel, HC
    Robertson, LI
    Mordhorst, L
    Gall, MA
    DIABETOLOGIA, 2005, 48 : A92 - A92
  • [23] Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes
    Hermansen, K
    Derezinski, T
    Kim, H
    Gall, MA
    DIABETOLOGIA, 2004, 47 : A273 - A274
  • [24] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S21 - S31
  • [25] Vildagliptin added to basal insulin glargine improves glycaemic control and reduces glycaemic excursions in type 2 diabetes
    Brooks, J.
    Bravis, V.
    Morgenstern, S.
    Hui, E.
    Gohel, B.
    Savarananthan, T.
    Carrolls, M.
    Devendra, D.
    DIABETOLOGIA, 2009, 52 : S294 - S295
  • [26] Insulin degludec allows for flexible daily dosing in type 1 diabetes, providing equal glycaemic control with less nocturnal hypoglycaemia than insulin glargine over 52 weeks
    Cooper, J. G.
    Mathieu, C.
    Hollander, P.
    Miranda-Palma, B.
    Franek, E.
    Bain, S.
    Larsen, J.
    Tamer, S. C.
    Russell-Jones, D. L.
    DIABETOLOGIA, 2012, 55 : S374 - S374
  • [27] Lower severe hypoglycemia risk: Insulin glargine versus NPH insulin in type 2 diabetes
    Dailey, George
    Strange, Poul
    AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (01): : 25 - 30
  • [28] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    DIABETOLOGIA, 2017, 60 : S36 - S37
  • [29] Risk of exercise-induced hypoglycaemia in patients with type 2 diabetes on intensive insulin therapy:: Comparison of insulin glargine with NPH insulin as basal insulin supplement
    Ploeckinger, Ursula
    Topuz, Mendaha
    Riese, Brigitte
    Reuter, Thomas
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 81 (03) : 290 - 295
  • [30] A meta-analysis of phase III/IIIb studies comparing insulin glargine with human NPH insulin in Type 2 diabetes: severe hypoglycaemia is less common with insulin glargine.
    Dailey, G
    Riddle, M
    Benedetti, MM
    Fritsche, A
    Lin, Z
    Salzman, A
    DIABETOLOGIA, 2003, 46 : A305 - A305
12345